Cellectar Shares Gain as Key Catalysts Approach
Published on 11/07/2025 at 08:10 | Redaktion boerse-global.de
Cellectar Biosciences saw its shares advance significantly during Thursday’s trading session following the company’s announcement of its quarterly earnings date. The financial community is particularly focused on the upcoming November 13 presentation, where investors anticipate crucial updates regarding the new drug application for the cancer therapeutic iopofosine I 131.
Market analysts project a third-quarter loss of $1.91 per share for the biopharmaceutical company. However, historical performance provides a glimmer of optimism. During the preceding quarter, Cellectar surpassed expectations by reporting a loss of $3.39 per share, notably better than the forecasted $3.60 per share loss. This positive earnings surprise of 5.83% demonstrated the company’s potential to outperform projections.
The organization’s financial Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
